부산대학교 도서관

However, given the previously documented high sustained virologic response rates of DAA therapy in HIV/HCV-coinfected liver transplant recipients, HCV recurrence was unlikely to have contributed significantly to poor outcomes in HCV-monoinfected or HIV/HCV-coinfected patients. Graph: Figure 2 One-year patient survival stratified by liver transplant quinquennium and infection status; (A) HIV-negative, HCV-negative; (B) HIV-negative, HCV-positive; (C) HIV-positive, HCV-negative; (D) HIV-positive, HCV-positive. Between 2000 and 2020, HIV/HCV-coinfected patients had the poorest one-year survival rates from all cohorts, followed by HIV-monoinfected patients, HCV-monoinfected patients and HCV/HIV-uninfected patients. While HIV/HCV-uninfected and HCV-monoinfected patients continued to show higher one- and five-year patient survival compared to HIV-monoinfected and HIV/HCV-coinfected patients, the disparity in mortality rates between groups became less evident in the post-DAA era (Figure 3). [Extracted from the article]